OUTCOMES IN NEOADJUVANT TRIALS


PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC).1

NeoSphere trial

TRYPHAENA trial

BERENICE trial

References